Published on 02/12/2025

Partner Transparency: Evidence Sharing Agreements

In the pharmaceutical industry, ensuring robust serialization and aggregation processes is essential for compliance with regulators such as the FDA, EMA, and MHRA. In this guide, we will cover the step-by-step design and implementation of Evidence Sharing Agreements (ESAs) focusing on serialization urs, aggregation hierarchy, master data governance, interface validation, reconciliation rules, and exception handling rework.

Understanding Serialization and Aggregation

Serialization is the process of assigning a unique identifier to each saleable unit of a prescription drug or biologic, establishing a direct track and trace mechanism from production to pharmacy. The purpose of serialization is to enhance supply chain security, reduce counterfeit drugs, and ensure compliance with regulations such as the Drug Supply Chain Security Act (DSCSA) in the US and the EU Falsified Medicines Directive (EU FMD).

Aggregation, on the other hand, involves grouping serialized items into higher-level packaging configurations. This enables simpler inventory management and facilitates the verification and recovery process in the supply chain. Understanding the aggregation hierarchy is critical for maintaining accuracy in data interpretation and compliance checks.

The significance of these processes is underscored by their alignment with data integrity principles, and the ALCOA+ framework (Attributable, Legible, Contemporaneous, Original, Accurate, and complete), which emphasizes the requirement for data reliability across platforms. Master data governance must also be established to ensure the consistency and accuracy of serialization data flows throughout an organization.

Planning Your Serialization and Aggregation Program

Successful serialization and aggregation initiatives require a comprehensive plan that adheres to industry standards and regulatory expectations. The first step is to establish a User Requirement Specification (URS) that outlines the system requirements necessary for effective serialization and aggregation processes.

Developing User Requirement Specifications (URS)

The URS serves as a critical document that captures the needs of the stakeholders and outlines what the system must achieve in terms of functionality, data integration, and compliance. When drafting a URS, consider the following:

• Stakeholders Involvement: Engage all relevant parties, including IT, operations, quality assurance, and regulatory affairs. Their input will shape the URS and address operational constraints.
• Define Use Cases: Clearly define the business use cases for serialization and aggregation. This includes tracking product from manufacturing through to dispensing at the pharmacy.
• Compliance and Regulatory Requirements: Ensure that all relevant regulatory standards are documented and reviewed, such as DSCSA compliance in the US and EU FMD requirements.
• Performance Criteria: Specify performance metrics that will be used to evaluate the system’s effectiveness, including audit trail review capabilities and system reliability.

Interface Validation and Master Data Governance

Once the URS is established, the next step involves validating interfaces between various systems used in the serialization and aggregation process. Interface validation ensures seamless integration across platforms, which is critical for data integrity and operational efficiency.

Interface Validation Steps

1. Identify Interfaces: Document all interfaces that will be integrated into the serialization and aggregation process. This typically includes systems such as ERP, WMS, and MES.
2. Risk Assessment: Conduct a risk assessment to identify potential failure points in data exchange and communication between systems.
3. Validation Protocol Development: Develop a validation protocol outlining the approach for testing interfaces, including test cases that reflect real-world scenarios.
4. Execute Validation Testing: Execute the validation test scripts according to the developed protocols, ensuring that data is accurately transmitted between systems.
5. Document Results: Document the results of validation testing, including any discrepancies or issues identified during the process.

Master Data Governance

Master data governance is fundamental in maintaining high-quality data throughout the serialization process. For effective governance, consider establishing the following:

• Data Ownership: Designate data stewards responsible for specific data sets, ensuring accountability and consistent data handling.
• Data Quality Standards: Define quality metrics for data integrity including completeness, consistency, and validity.
• Change Control Mechanisms: Implement change control processes for any modifications to master data that affect serialization and aggregation.

Reconciliation Rules and Exception Handling

Reconciliation processes are vital for ensuring that the data captured during serialization and aggregation accurately represents product movement within the supply chain. Establishing reconciliation rules will help identify discrepancies between serialized data and physical inventories.

Developing Reconciliation Rules

• Define Matching Criteria: Establish criteria under which serialized products will be compared against master data records or system-generated reports.
• Frequency of Reconciliation: Determine how often reconciliation will occur, taking into consideration regulatory requirements and operational needs.
• Reconciliation Workflows: Design workflows that streamline the reconciliation process, detailing how to handle discrepancies when they arise.

Exception Handling and Rework Procedures

When discrepancies occur, a structured exception handling process is crucial to restore integrity to the serialization data. Define a clear pathway for handling exceptions:

1. Identify the Issue: Upon identifying a serialization error, determine whether the issue arose from data entry, system malfunction, or user error.
2. Document the Exception: Record all details regarding the exception for future audits and evaluations.
3. Develop a CAPA Plan: Utilize a Corrective and Preventive Action (CAPA) approach to address the root cause of the exception, preventing recurrence.
4. Implement Rework Procedures: Establish detailed rework procedures that align with regulatory expectations and ensure data consistency during the correction process.

Audit Trails and Compliance Monitoring

Continuous monitoring of the serialization and aggregation process is essential for compliance and maintaining traceability. Implementing robust audit trails ensures that all actions within the system are tracked effectively.

Audit Trail Review Practices

Regular audit trail reviews can help identify anomalies and ensure compliance with data integrity standards:

• Automated Audit Trails: Utilize automated systems to maintain audit trails, ensuring all transaction data is logged in real-time.
• Regular Review Frequency: Establish the frequency of independent reviews of the audit trails to ensure continuous compliance.
• Investigating Discrepancies: Have processes in place to investigate discrepancies found during audit trail reviews, emphasizing root cause analysis and corrective measures.

Data Integrity and Regulatory Compliance

Understanding the principles of data integrity (ALCOA+) is crucial in implementing effective serialization and aggregation systems. Ensuring compliance with policies set by authorities such as the EMA and strict adherence to guidelines is vital for successful audits and regulatory submissions.

Conclusion: Effective Serialization Program Management

Establishing effective serialization and aggregation practices is not only a regulatory requirement but a pivotal aspect of ensuring patient safety and enhancing supply chain transparency in the pharmaceutical industry. By investing in robust URS, interface validations, master data governance, and clear reconciliation rules, organizations can significantly improve their serialization and aggregation efforts. Continuous monitoring and stringent audit trail practices will ensure compliance and data integrity, laying the groundwork for a resilient pharmaceutical supply chain.

As regulatory expectations evolve, ongoing education and process adjustments are essential for staying compliant and maintaining operational excellence. Employing these best practices will yield enhanced efficiency while fostering a culture of transparency and accountability within the organization.